DNA 和 RNA 银行服务市场 - 全球产业规模、份额、趋势、机会和预测，按类型、应用、最终用途、地区和竞争细分，2020-2030 年

2024 年全球 DNA 和 RNA 银行服务市值为 79.7 亿美元，预计到 2030 年将达到 121.8 亿美元，预测期内复合年增长率为 7.29%。由于研究、诊断和治疗应用对遗传物质储存和分析的需求不断增长，全球 DNA 和 RNA 银行服务市场已成为生物银行领域的关键部门。该市场包括保存从各种来源（包括血液、组织和唾液）收集的 DNA 和 RNA 样本，以确保其完整性以供未来的科学调查使用。个人化医疗的发展和基因组学的进步极大地推动了对这些银行服务的需求，因为研究人员和医疗保健专业人员寻求利用遗传资讯来开发量身定制的治疗方法并增强疾病预防策略。基因组研究资金的增加和旨在了解遗传性疾病的措施的增加进一步刺激了市场扩张。也建立了监管机构和道德准则，以确保对遗传材料进行负责任的管理和利用，这对于建立公众对生物样本库实践的信任至关重要。新一代定序和自动样本处理系统等技术进步提高了 DNA 和 RNA 库的效率和准确性，从而增强了它们对学术机构、医院和生物技术公司的吸引力。

市场概况
预测期	2026-2030
2024 年市场规模	79.7亿美元
2030 年市场规模	121.8亿美元
2025-2030年复合年增长率	7.29%
成长最快的细分市场	疗法
最大的市场	北美洲

主要市场驱动因素

基因组研究的进展

对遗传性疾病的认识不断提高

生物样本库的技术创新

主要市场挑战

技术进步和基础设施成本

样品品质与诚信管理

主要市场趋势

生物製药产业的发展

更加重视预防性医疗保健

细分市场洞察

类型洞察

应用洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球 DNA 与 RNA 银行服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型（运输服务、加工服务、储存服务、品质控制服务、资料储存、其他）
  • 按应用（治疗、药物发现和临床研究、临床诊断、其他）
  • 按最终用途（学术研究、製药和生物技术公司、医院和诊断中心、其他）
  • 按公司划分 (2024)
  • 按地区
• 市场地图

第 6 章：北美 DNA 与 RNA 银行服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按申请
  • 按最终用途
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲 DNA 与 RNA 银行服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按申请
  • 按最终用途
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区 DNA 与 RNA 银行服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按申请
  • 按最终用途
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲 DNA 与 RNA 银行服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按申请
  • 按最终用途
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲 DNA 和 RNA 银行服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按申请
  • 按最终用途
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第14章：竞争格局

• DNA Genotek Inc.
• EasyDNA
• 23andMe, Inc.
• Biobanking.com
• US Biolab Corporation, Inc
• ProteoGenex
• Thermo Fisher Scientific, Inc.
• deCODE genetics
• Azenta Life Sciences
• Infinity BiologiX LLC (Sampled).

第 15 章：策略建议

第16章调查会社について・免责事项

Global DNA & RNA Banking Services Market was valued at USD 7.97 Billion in 2024 and is expected to reach USD 12.18 Billion by 2030 with a CAGR of 7.29% during the forecast period. The Global DNA & RNA Banking Services Market has emerged as a pivotal sector in the biobanking landscape, driven by the increasing demand for genetic material storage and analysis for research, diagnostics, and therapeutic applications. This market encompasses the preservation of DNA and RNA samples collected from various sources, including blood, tissue, and saliva, ensuring their integrity for future scientific inquiries. The growth of personalized medicine and advancements in genomics have significantly propelled the demand for these banking services, as researchers and healthcare professionals seek to harness genetic information to develop tailored treatments and enhance disease prevention strategies. The rise in genomic research funding and initiatives aimed at understanding genetic disorders have further stimulated market expansion. Regulatory bodies and ethical guidelines have also been established to ensure the responsible management and utilization of genetic materials, which is essential for building public trust in biobanking practices. Technological advancements, such as next-generation sequencing and automated sample handling systems, have improved the efficiency and accuracy of DNA and RNA banking, thereby enhancing their appeal to academic institutions, hospitals, and biotechnology companies.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 7.97 Billion
Market Size 2030	USD 12.18 Billion
CAGR 2025-2030	7.29%
Fastest Growing Segment	Therapeutics
Largest Market	North America

Key Market Drivers

Advancements in Genomic Research

Rapid advancements in genomic research are profoundly influencing the Global DNA & RNA Banking Services Market. The emergence of high-throughput sequencing technologies and advanced bioinformatics tools has revolutionized the ability of researchers to analyze vast amounts of genetic data quickly and efficiently. This capability is particularly crucial for understanding complex diseases, such as cancer and genetic disorders, where traditional research methods may fall short. By enabling the analysis of large-scale genomic data, these technologies facilitate the identification of genetic variations that can inform the development of targeted therapies tailored to individual patients. For instance, In January 2021, the UK launched the Rare Disease Framework, aimed at improving diagnosis, awareness, care, and treatment access for 3.5 million rare disease patients over five years. This initiative highlights the increasing demand for DNA and RNA banking services, as timely genetic analysis is essential for effective management and treatment of rare diseases.

In this evolving landscape, academic institutions and research organizations are increasingly relying on DNA and RNA banking services to secure high-quality biological samples for both ongoing and future studies. These samples serve as critical resources for research, allowing scientists to investigate the genetic underpinnings of diseases and assess potential treatment responses. The preservation of genetic material in biobanks ensures that researchers have access to diverse and representative samples, which enhances the robustness of their findings.

The trend is further supported by rising government funding and private investments in genomics research, creating a favorable environment for biobanking services. Funding initiatives are designed to support groundbreaking research projects that require access to high-quality biological materials, thereby accelerating the pace of discovery in genetic research. These investments not only facilitate the establishment of state-of-the-art biobanks but also enhance collaboration among researchers, healthcare providers, and biotechnology firms. Such collaborations foster innovation in genetic research and its applications, paving the way for new diagnostic tools and therapeutic options. The ongoing advancements in genomic research underscore the critical role of DNA and RNA banking services in the scientific community. By providing essential resources and facilitating collaboration, these services are instrumental in driving forward the frontiers of genomic knowledge and its practical applications in healthcare.

Rising Awareness of Genetic Disorders

The rising awareness of genetic disorders is emerging as a critical driver for the Global DNA & RNA Banking Services Market. As healthcare professionals and the general public become more informed about the profound impact genetics has on health, the demand for genetic testing and associated biobanking services has seen a significant uptick. This heightened awareness is fueled by various factors, including advances in medical research, increased media coverage, and educational initiatives that focus on the importance of genetics in disease prevention and management. Genetic disorders, which encompass hereditary diseases and certain types of cancer, necessitate precise genetic analysis for accurate diagnosis and effective treatment planning. For instance, according to the American Cancer Society's 2022 report, the United States is projected to see 1,918,030 new cancer cases and 609,360 cancer-related deaths in 2022, including approximately 350 daily deaths from lung cancer, the leading cause of cancer mortality. This rising incidence emphasizes the critical need for DNA and RNA banking services, as these resources are essential for advancing cancer research, enabling personalized treatment approaches, and improving outcomes for patients diagnosed with various types of cancer. As a result, hospitals, clinics, and diagnostic laboratories are increasingly utilizing DNA and RNA banking services to obtain and store samples for testing. This demand for biobanking is driven by the need for reliable and accessible genetic material, which can be used to identify mutations, assess disease risk, and guide therapeutic decisions.

The growing recognition of the importance of genetic testing emphasizes the need for robust biobanking services that ensure the integrity and quality of genetic material. Healthcare providers are now more focused on sourcing high-quality DNA and RNA samples, as these are essential for accurate test results and meaningful clinical interpretations. The presence of well-maintained biobanks enhances the capability of healthcare institutions to conduct comprehensive genetic analyses, ultimately improving patient outcomes.

Public health campaigns aimed at educating individuals about genetic risk factors and the advantages of early diagnosis are further contributing to the growing utilization of DNA and RNA banking services. These initiatives inform the public about the benefits of genetic testing in managing hereditary conditions and promoting proactive healthcare measures. Consequently, the increasing awareness of genetic disorders not only drives demand for genetic testing but also highlights the essential role of biobanking services in the healthcare ecosystem, fostering advancements in personalized medicine and enhancing patient care.

Technological Innovations in Biobanking

Technological innovations are fundamentally reshaping the Global DNA & RNA Banking Services Market, significantly enhancing the efficiency and effectiveness of biobanking operations. These advancements span various stages of biobanking, including sample collection, processing, and storage, enabling biobanks to uphold high-quality standards for genetic materials. For instance, the introduction of automated systems for sample handling and processing minimizes the risk of contamination and human error, thereby ensuring the integrity of stored samples. This level of precision is vital in maintaining the reliability of genetic materials, which is crucial for both research and clinical applications.

Next-generation sequencing (NGS) technologies have revolutionized the field of genetics by allowing for rapid and comprehensive genetic analysis. NGS provides deeper insights into genetic variations, enhancing the value of biobanked samples for a wide range of research initiatives and clinical applications. Researchers can now conduct more extensive genetic analyses, leading to discoveries that may have been unattainable with traditional sequencing methods. This capability not only accelerates research timelines but also expands the potential for novel therapeutic developments.

The integration of advanced data management systems is transforming how biobanks operate. These systems enable biobanks to efficiently organize, track, and manage samples, facilitating easier access for researchers and healthcare providers. Improved data management ensures that critical information about each sample is readily available, enhancing collaboration and expediting research projects. Robust data systems are essential for maintaining compliance with regulatory standards, thereby bolstering the credibility of biobanking operations. As these technologies continue to evolve, they are set to further streamline biobanking processes, making DNA and RNA banking services more appealing to a diverse array of potential clients, including academic institutions, hospitals, and pharmaceutical companies. The promise of enhanced efficiency, quality assurance, and data management underscores the transformative impact of technological innovations in the biobanking sector, positioning it for sustained growth and increased relevance in the broader healthcare landscape.

Key Market Challenges

Technological Advancements and Infrastructure Costs

Technological advancements in genomic research and biobanking have transformed the landscape of DNA and RNA banking services; however, they also present significant challenges, particularly concerning infrastructure costs. As new technologies, such as high-throughput sequencing and advanced bioinformatics tools, emerge, biobanks must continually upgrade their equipment and processes to stay competitive. The financial burden of implementing these technologies can be substantial, especially for smaller or emerging biobanks that may lack sufficient funding. The rapid pace of technological advancement can render existing systems obsolete, necessitating further investment in new technologies to maintain operational efficiency and data integrity. This situation creates a financial strain on biobanks, limiting their ability to invest in other critical areas such as staff training, sample quality control, and research collaboration. The integration of advanced technologies requires specialized expertise, and there is a shortage of skilled professionals in the field, which can further hinder biobanks' ability to leverage new advancements effectively. To overcome these challenges, biobanks need to develop strategic partnerships with technology providers, seek funding from governmental and private sources, and explore innovative financing models that can support ongoing technological investments while ensuring their services remain accessible and affordable.

Sample Quality and Integrity Management

Maintaining the quality and integrity of DNA and RNA samples is a critical challenge for the Global DNA & RNA Banking Services Market. The viability of genetic material is crucial for research and clinical applications, and any compromise in sample quality can lead to erroneous results and wasted resources. Various factors can impact sample integrity, including collection methods, storage conditions, and the duration of storage. For instance, improper collection techniques or inadequate storage temperatures can result in degradation of samples, rendering them unsuitable for analysis. The need for long-term storage poses unique challenges, as biobanks must implement rigorous protocols to ensure that samples remain viable over extended periods. This involves monitoring storage conditions, implementing quality control measures, and conducting regular audits to assess sample integrity. Biobanks must also address the risk of contamination, which can occur during sample handling or storage. Ensuring sample quality requires ongoing training for staff, investments in sophisticated storage systems, and adherence to best practices in sample management. Failure to maintain high standards for sample quality can undermine the credibility of biobanks and limit their ability to attract clients, ultimately impacting the growth of the DNA and RNA banking services market.

Key Market Trends

Growth of Biopharmaceutical Industry

The rapid growth of the biopharmaceutical industry is a key driver for the Global DNA & RNA Banking Services Market. In recent years, biopharmaceutical companies have become increasingly reliant on genetic research to develop novel therapeutics, including biologics and gene therapies. This shift toward precision medicine underscores the importance of understanding the genetic basis of diseases, as it enables the creation of targeted treatments that can improve patient outcomes. To achieve this, biopharmaceutical companies require access to high-quality DNA and RNA samples for their research and development activities, making biobanks invaluable resources.

Biobanks play a critical role in providing these essential resources, offering a diverse array of high-quality genetic materials that enable biopharmaceutical companies to conduct comprehensive genetic analyses. These analyses are crucial for identifying genetic markers associated with specific diseases, evaluating treatment responses, and validating findings in clinical settings. The quality and integrity of the samples provided by biobanks are paramount, as they directly impact the reliability of research outcomes and the overall success of drug development processes.

The growing trend of collaboration between biopharmaceutical companies and academic institutions for research purposes further fuels the demand for DNA and RNA banking services. These partnerships often focus on translating cutting-edge genetic research into practical therapeutic applications. By pooling resources and expertise, biopharmaceutical firms and academic researchers can advance their collective understanding of complex diseases, leading to the discovery of innovative treatment strategies. This collaborative approach highlights the need for robust biobanking services that can accommodate the specific requirements of both parties. As the biopharmaceutical industry continues to expand, it will increasingly depend on biobanking services to support its innovative research efforts. The ongoing evolution of this sector, characterized by rapid technological advancements and an increasing focus on personalized medicine, emphasizes the vital role of DNA and RNA banking services in driving the development of next-generation therapeutics and improving healthcare outcomes worldwide.

Increased Focus on Preventive Healthcare

The rising focus on preventive healthcare is a crucial driver for the Global DNA & RNA Banking Services Market. As healthcare systems worldwide transition their emphasis from reactive to preventive measures, the importance of genetic screening and risk assessment has become increasingly pronounced. This shift is largely driven by a growing understanding that many diseases have a genetic component, and early identification of genetic predispositions can lead to more effective preventive strategies. Individuals and healthcare providers are increasingly recognizing the value of understanding genetic predispositions to diseases. By identifying genetic markers associated with specific health conditions, people can make informed lifestyle choices that mitigate their risk factors. For example, individuals at higher genetic risk for conditions such as heart disease, diabetes, or certain cancers can adopt preventive measures such as dietary changes, increased physical activity, or regular health screenings. This proactive approach empowers individuals to take charge of their health, promoting a culture of prevention rather than reaction.

Consequently, the demand for DNA and RNA banking services is growing, as these services provide the necessary genetic material for risk assessment and preventive healthcare initiatives. Biobanks offer a repository of high-quality DNA and RNA samples that can be utilized in genetic testing and research aimed at identifying risk factors for various diseases. The integration of genetic data into preventive care not only enhances individual health decisions but also enables healthcare providers to develop targeted interventions tailored to an individual's genetic profile.

This preventive focus can lead to significant cost savings for healthcare systems by reducing the incidence of chronic diseases and minimizing the need for costly treatments. By catching potential health issues early through genetic screening, healthcare providers can implement interventions that lead to better health outcomes. As the trend toward preventive healthcare continues to gain momentum, the market for DNA and RNA banking services is poised for substantial growth. The increasing recognition of the importance of genetic insights in disease prevention positions biobanks as essential partners in the future of healthcare, driving innovation and improving population health on a global scale.

Segmental Insights

Type Insights

Based on the Type, in the Global DNA & RNA Banking Services Market, Processing Services are currently dominating, primarily due to their critical role in ensuring the quality and integrity of genetic materials. The processing phase encompasses the collection, isolation, purification, and analysis of DNA and RNA samples, which are essential steps in preparing these samples for subsequent storage and research applications. This phase is vital, as the quality of the processed samples directly influences the reliability of genetic analyses, making it a top priority for biobanks and research institutions.

The demand for high-quality processed samples is driven by the increasing focus on precision medicine and genetic research, where the accuracy of results is paramount. Processing services that employ advanced techniques and technologies, such as automation and next-generation sequencing (NGS), enhance the efficiency and reliability of sample preparation. As a result, many biopharmaceutical companies, research institutions, and clinical laboratories are investing heavily in high-quality processing services to support their innovative research initiatives.

Application Insights

Based on the application, in the Global DNA & RNA Banking Services Market, the Therapeutics, application segment is currently dominating. This dominance can be attributed to the increasing emphasis on personalized medicine, where understanding an individual's genetic makeup is essential for developing targeted therapies. Biopharmaceutical companies and research institutions are leveraging DNA and RNA banking services to obtain high-quality genetic materials, which are crucial for researching and developing novel therapeutics, including biologics and gene therapies.

The growing prevalence of genetic disorders and complex diseases, such as cancer, diabetes, and cardiovascular diseases, has intensified the focus on therapeutic development. By utilizing genetic data from biobanks, researchers can identify genetic mutations and biomarkers that contribute to disease progression. This information is instrumental in formulating tailored treatment plans that can significantly enhance patient outcomes. Advancements in technologies like CRISPR and gene editing are further driving the need for robust DNA and RNA samples, as these techniques rely heavily on accurate genetic information.

Regional Insights

North America is currently the dominant region in the Global DNA & RNA Banking Services Market. This dominance can be attributed to several factors that create a favorable environment for biobanking services. North America, particularly the United States, is home to a large number of leading research institutions, universities, and pharmaceutical companies. These entities invest significantly in genetic research, driving demand for DNA and RNA banking services. The availability of advanced technologies and facilities facilitates extensive research, including drug development and personalized medicine initiatives.

With a growing awareness of genetic disorders and the importance of genetic testing, there is an increasing demand for DNA and RNA samples for diagnostics and therapeutic development in North America. This trend is driving healthcare providers and research organizations to utilize biobanking services more extensively. The North American region benefits from substantial government funding and support for biomedical research. Initiatives from agencies such as the National Institutes of Health (NIH) and other public and private organizations promote genetic research, further boosting the need for reliable biobanking services.

Key Market Players

• DNA Genotek Inc
• EasyDNA
• 23andMe, Inc.
• Biobanking.com
• US Biolab Corporation, Inc
• ProteoGenex
• Thermo Fisher Scientific, Inc.
• deCODE genetics
• Azenta Life Sciences
• Infinity BiologiX LLC (Sampled)

Report Scope:

In this report, the Global DNA & RNA Banking Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA & RNA Banking Services Market, By Type:

• Transportation Service
• Processing Service
• Storage Service
• Quality Control Service
• Data Storage
• Others

DNA & RNA Banking Services Market, By Application:

• Therapeutics
• Drug Discovery & Clinical Research
• Clinical Diagnostics
• Others

DNA & RNA Banking Services Market, By End Use:

• Academic Research
• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Centers
• Others

DNA & RNA Banking Services Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA & RNA Banking Services Market.

Available Customizations:

Global DNA & RNA Banking Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global DNA & RNA Banking Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Transportation Service, Processing Service, Storage Service, Quality Control Service, Data Storage, Others)
  • 5.2.2. By Application (Therapeutics, Drug Discovery & Clinical Research, Clinical Diagnostics, Others)
  • 5.2.3. By End Use (Academic Research, Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Centers, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America DNA & RNA Banking Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA & RNA Banking Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End Use
  • 6.3.2. Mexico DNA & RNA Banking Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End Use
  • 6.3.3. Canada DNA & RNA Banking Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End Use

7. Europe DNA & RNA Banking Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France DNA & RNA Banking Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End Use
  • 7.3.2. Germany DNA & RNA Banking Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom DNA & RNA Banking Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy DNA & RNA Banking Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain DNA & RNA Banking Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End Use

8. Asia-Pacific DNA & RNA Banking Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China DNA & RNA Banking Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End Use
  • 8.3.2. India DNA & RNA Banking Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End Use
  • 8.3.3. South Korea DNA & RNA Banking Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End Use
  • 8.3.4. Japan DNA & RNA Banking Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia DNA & RNA Banking Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End Use

9. South America DNA & RNA Banking Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil DNA & RNA Banking Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina DNA & RNA Banking Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia DNA & RNA Banking Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End Use

10. Middle East and Africa DNA & RNA Banking Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa DNA & RNA Banking Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia DNA & RNA Banking Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE DNA & RNA Banking Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. DNA Genotek Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. EasyDNA
• 14.3. 23andMe, Inc.
• 14.4. Biobanking.com
• 14.5. US Biolab Corporation, Inc
• 14.6. ProteoGenex
• 14.7. Thermo Fisher Scientific, Inc.
• 14.8. deCODE genetics
• 14.9. Azenta Life Sciences
• 14.10. Infinity BiologiX LLC (Sampled).

15. Strategic Recommendations

16. About Us & Disclaimer